Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark.
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Spark Therapeutics, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2021
Details:
Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cobra Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020